

Your lab, Our tests

Labcorp's FDA-authorized tissue and liquid biopsy kitted assays eliminate the burden of full validation, requiring only verification steps.



PGDx elio® tissue complete
The first FDA-cleared
pan-solid tumor tissue kitted assay

PGDx elio® plasma focus™ Dx
The first and only FDA-authorized
pan-solid tumor liquid biopsy kitted assay

Key benefits of Labcorp's FDA-authorized kitted assays

Eliminate the burden of full validation, enabling a go-live in as few as six weeks

- FDA-authorized assays eliminate the burden of full validation requiring only on-site verification steps
- White glove implementation support and dedicated project management accelerates path to go-live

Enable seamless tissue-to-liquid reflexing when tissue results fail or tissue insufficient

- The same validated chemistry, bioinformatics servers, and DNA sequencers enable efficient, streamlined workflows

High clinical success rates and guideline-driven targets ensure robust, reliable and actionable results for pan solid tumors

- Target guideline-driven biomarkers for pan-solid tumors
 - 500+ genes, TMB and MSI for tissue-based profiling
 - 33 clinically actionable genes for ctDNA-based testing
- High clinical success rates:
 - PGDx elio tissue complete: 92%
 - PGDx elio plasma focus Dx: 96%

Sample and data ownership open avenues for both research and clinical studies

- Ensure sample chain of custody for accurate reporting
- Retain access to archival samples and data to drive novel insights

PGDx elio tissue complete

The first FDA-cleared solid tumor tissue kitted assay for pan-cancer tumors



Assay features:

- SNVs: 505 genes
- Indels: 505 genes
- Amplification: 1 gene
- Translocations: 4 genes
- Genomic Signatures: TMB and MSI

Assay specifications:

- Assay time to results: 4-5 days
- Bioinformatics: Single automated pipeline
- Sequencer: NextSeq550 Dx
- Variant allele frequency (VAF): Down to 2%
- Clinical success rate: 92%
- Specificity: 99.9% specificity across all variant classes
- Rigorously validated: Our accuracy study assessed more than 30 different solid tumor types



Learn more about
PGDx elio tissue complete

PGDx elio plasma focus Dx

The first and only FDA-authorized liquid biopsy kitted assay for pan-cancer tumors



Assay features:

- SNVs: 33 genes
- Indels: 33 genes
- Amplifications: 5 genes
- Translocations: 3 genes

Assay specifications:

- Assay time to results: 4-5 days
- Bioinformatics: Single automated pipeline
- Sequencer: NextSeq550 Dx
- Variant allele frequency (VAF): Down to 0.1%
- Clinical success rate: 96%
- Specificity: 100% specificity for clinically significant sequence variants, amplifications and translocations
- Rigorously validated: Our accuracy study assessed more than 30 different solid tumor types



Learn more about
PGDx elio plasma focus Dx

For more information, contact your local Labcorp sales representative or email pgdxinfo@labcorp.com.